Clinical trialsOfficial

ANSM bans direct lab sales of furosemide to pharmacies as shortage seen lasting into 2027

🇫🇷 ANSM · Wed 18 Nov 2026

France's medicines agency is combining imports, extra production, unit dispensing and compounded capsules to protect treatment continuity for patients during furosemide 20 mg and 40 mg supply tensions.

France's medicines agency ANSM said on 18 November 2026 that severe supply tensions affecting furosemide 20 mg and 40 mg medicines are continuing and should last several more months in 2027. It is reinforcing earlier measures and adding new ones to limit the risk of patients losing access to treatment. The agency attributes the persistent difficulties to supply problems at the marketing company Viatris.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Official source: ANSM ↗

Article written by VigiEye from the official source (ANSM). AI-assisted; check the source before acting.